The scan that finds it is quick, safe, and has been around for years. Almost no cardiologist used it until a drug gave them a reason to look.
A non-invasive scan could spot ATTR cardiac amyloidosis, a common, deadly, long-overlooked cause of heart failure in the elderly, years before doctors used it. Diagnoses only surged after tafamidis (Vyndaqel) was approved for the heart in 2019. The treatment didn't create the disease; it created the diagnosis. The backstory, the economics, and why it matters.
Prometheus gave IBD its best shot at oncology-style patient selection: a companion diagnostic for its anti-TL1A drug, tulisokibart. Merck paid $10.8 billion, then built its Phase 3 trials to enroll everyone. The more crowded the anti-TL1A field gets, the stronger the case for a precision-medicine approach, even as the science has yet to deliver one.
Prometheus built a companion diagnostic to pick the ulcerative colitis patients its anti-TL1A antibody tulisokibart would help, and Merck bought the company for $10.8B. But when Merck launched the Phase 3 program in 2023 (soon after the acquisition), it chose to enroll everyone and demote the test to a secondary endpoint, a design choice fixed years before the trials read out. The now-positive Phase 3 confirms it, and the rest of the anti-TL1A class (Roche, Sanofi/Teva, Spyre, the newly-launched Bionyra) competes on potency and half-life, not patient selection. Yet the more crowded the field gets, the stronger the case for a precision-medicine approach, even as the science has yet to deliver it.
Of 214 industry IBD trials terminated or withdrawn over two decades, only ~23% stopped for efficacy or safety. The rest ran out of patients, money, or corporate priority — the trial failed, not the biology.
We read the sponsor’s stated reason — the ClinicalTrials.gov whyStopped note — on all 214 terminated or withdrawn industry IBD trials. Business and portfolio decisions are the single largest cause (36%); inability to enroll is next (22%). Lack of efficacy (20%) and safety (4%) together are only ~23% — so when an IBD trial is pulled early, ~77% of the time the reason says nothing about whether the drug worked.
Alnylam's two siRNA drugs hit the same liver target. One failed an FDA review in 2023. Two years later the other was approved for both forms of ATTR amyloidosis. The mechanism didn't change. The trial design did.
In September 2023 an FDA advisory committee voted 9-3 that patisiran's benefit supported approval for cardiac ATTR amyloidosis. The FDA rejected it anyway. Eighteen months later it approved vutrisiran — a near-identical Alnylam siRNA against the same liver target — for both forms of ATTR at once. Patisiran's APOLLO-B was 360 patients, 12 months, a six-minute-walk endpoint (+14.7 m, p=0.0162) with a secondary composite that missed at a win ratio of 1.27. Vutrisiran's HELIOS-B was 655 patients, up to 36 months, a hard mortality-plus-CV-events composite cut by 28%. Same mechanism, opposite verdicts — the molecule never changed, the trial did.
Eleven years after approval, Entyvio remains the only IBD drug that acts only in the gut — and two large pharma programs have failed trying to replicate it.
Tysabri (natalizumab) blocks α4 integrin broadly — and 541 patients developed fatal brain infections. Entyvio (vedolizumab) blocks only α4β7, which binds MAdCAM-1 on gut endothelium. One Greek letter difference. Over a million patient-years, no REMS, no MRI surveillance. Takeda's $6 billion franchise is built on that subtraction — and on a head-to-head trial where vedolizumab beat Humira directly in ulcerative colitis.
One arm grabs the cancer cell. The other grabs a T-cell. The bispecific forces them together.
CAR-T cell therapy works but takes weeks to manufacture and costs $400K+ per patient. T-cell engager bispecific antibodies do the same job as an injectable drug - no cell extraction, no manufacturing delay. Ten are now FDA-approved across myeloma, lymphoma, leukemia, and solid tumors, competing directly with CAR-T in the same diseases.
Pfizer, Amgen, Lilly, Merck, and Astellas all failed at IGF-1R in cancer. Then a shelved Roche antibody became the only effective treatment for thyroid eye disease. Same receptor, completely different biology.
Five major pharmas spent two decades chasing IGF-1R as a cancer target. Every Phase 3 trial failed. The only IGF-1R drug ever approved is for thyroid eye disease — Tepezza, which generated $1.9 billion in 2024 and 8x exceeded its acquirer's peak forecast. Eleven more IGF-1R-for-TED programs are now in clinical trials, including the literal cancer-graveyard compound being resurrected by Sling Therapeutics. Targets don't travel. Disease context decides.
Nobody knew why it caused birth defects for 50 years. The answer launched a new era of drug design.
The worst drug disaster in pharmaceutical history accidentally revealed how to hijack the cell's protein disposal system. Celgene turned thalidomide derivatives into a $12.8B franchise without knowing the mechanism. When scientists finally identified the target in 2010, it launched targeted protein degradation - now one of the most promising modalities in drug development, with its first FDA-approved drug.
Two drugs finally broke through. They work only before most patients are ever diagnosed.
Alzheimer's drug development has a 99.6% failure rate - the highest of any disease. Between 2003 and 2021, zero new treatments were approved while $42.5 billion was spent on clinical trials. Then lecanemab and donanemab broke through. But 27% slowing of cognitive decline, brain swelling in up to 1 in 4 patients, and $26,000/year raises the question: is this enough?
A decade of data. From Spinraza to Mounjaro, what the designations tell you.
We analyzed every novel drug the FDA approved from 2016 to 2025 - 459 drugs across 10 years - and tagged each one with its regulatory designations. Half target rare diseases. 42% are first-in-class. Breakthrough therapy doubled. From Spinraza to Mounjaro, the patterns tell you more about how the FDA works than any single approval ever could.
Every approved IBD drug fights inflammation. None of them touch fibrosis. TL1A does both.
30% of Crohn's disease patients will need surgery within ten years of diagnosis - not because their drugs failed to control inflammation, but because no approved drug stops the scar tissue that narrows their bowel. TL1A is the first target that could change that. Here is the biology behind the $18 billion bet.
It took 40 years to drug KRAS. The real competition started the day it worked.
KRAS mutations drive roughly 30% of all cancers. For four decades, no one could drug it. In 2021, sotorasib cracked the target. Now three approaches - next-gen G12C, G12D inhibitors, and pan-KRAS degraders - are racing to turn a proven mechanism into a blockbuster.
How a genetic discovery in 2003 launched a $5 billion market.
In 2006, researchers found people born with broken copies of PCSK9 had very low cholesterol and almost no heart attacks. They were healthy. That was the signal. Four drugs across three different modalities now target the same gene - a combined market exceeding $5 billion in 2025.
The difference explains everything about how biologics compete.
When a small-molecule patent expires, generics arrive at 90% off. When a biologic patent expires, biosimilars arrive years later at a modest discount. Same industry, completely different economics. The reason is molecular.
How to read a drug name you have never seen before.
Pembrolizumab. Adalimumab. Semaglutide. These look like random syllables. They're not. Every generic drug name follows a WHO naming code that encodes the drug class, mechanism, and modality directly into its name. Once you know the suffixes, you can decode any drug on sight.
